Importantly, the glutaminase inhibitor CB-839, impaired cell growth in a panel of tumor cells including melanoma, colon, renal, bone, squamous and urinary-tract cancers with KEAP1 LOF mutations while the use of KI696, a small-molecule activator of NRF2, conversely sensitized KEAP1 WT cancer cells previously refractory to CB-839 [255]. The gene discussed is KEAP1; the disease is melanoma.